Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05891834 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 7, 2023
Last Update Posted : May 9, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity Metabolic Syndrome | Drug: INV-202 Drug: Placebo | Phase 2 |
This will be a 2-part study. Part A will be a randomized, double-blind, placebo-controlled, dose ranging, multicenter study assessing the efficacy, safety, tolerability, and PK of INV-202 for the treatment of adult participants with obesity (BMI 30 kg/m2) and metabolic syndrome.
An informed consent form (ICF) must be signed by the participant before any study-related procedures are performed.
Each participant will be allowed 1 retest during the screening period if they have an abnormal test result not meeting eligibility criteria that is deemed transient by the investigator. Participants who did not meet all eligibility criteria may be re-screened once, with approval of the medical monitor.
Participants will return to the study site at Weeks 4, 8, 12 and 16. At these visits, the same assessment as baseline will be completed.
During Part A, a subset of approximately 20 to 30 participants from an estimated 3 to 4 study sites will have DEXA performed at baseline and Week 16 for exploratory assessments of change in total body fat percentage and skeletal muscle mass. Additional exploratory measures will include lung function with oscillometry. Any participant who withdraws from Part A before completing treatment will be requested to return for an early termination visit, at which time the procedures normally scheduled for the Week 16 visit will be conducted.
Participants completing Part A will be eligible to enroll to the open-label extension (OLE), Part B, if they did not have significant noncompliance with study drug, visits, or procedures, and did not meet any withdrawal criteria. During Part B, the efficacy and safety of INV-202 20 mg daily (pending results of chronic toxicology studies and/or findings from this and other ongoing clinical studies, the alternative dose would be 10 mg) will be further evaluated over an additional 36 weeks, through Week 52.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 243 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of 3 Doses of INV-202 With an Optional Open-Label Extension in Patients With Obesity and Metabolic Syndrome |
| Actual Study Start Date : | September 8, 2023 |
| Estimated Primary Completion Date : | July 1, 2024 |
| Estimated Study Completion Date : | March 1, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Low dose
INV-202, 10 mg
|
Drug: INV-202
tablet, once daily, oral |
|
Experimental: High dose
INV-202, 50 mg
|
Drug: INV-202
tablet, once daily, oral |
|
Placebo Comparator: Placebo
Placebo Matching size and number of tablets
|
Drug: Placebo
tablet, once daily, oral |
|
Experimental: Middle Dose
INV-202, 20 mg
|
Drug: INV-202
tablet, once daily, oral |
- To evaluate the effect of INV-202 on body weight loss in participants with obesity and metabolic syndrome [ Time Frame: Week 16 ]Mean change from baseline in body weight at Week 16 for INV-202 versus placebo
- To evaluate the effect of INV-202 on weight (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean percent change from baseline at each site visit for the following:
Percent change in weight
- To evaluate the effect of INV-202 on waist circumference (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean change from baseline at each site visit for the following:
Change in waist circumference
- To evaluate the effect of INV-202 on lipids (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean change from baseline at each site visit for the following:
Change in lipids (LDL, VLDL, HDL, total cholesterol, ApoB) results by central laboratory testing
- To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean change from baseline at each site visit for the following:
Change in markers of glucose control (HgbA1C) results by central laboratory testing
- To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean change from baseline at each site visit for the following:
Change in markers of glucose control (insulin) results by central laboratory testing
- To evaluate the effect of INV-202 on glucose control (marker of metabolic syndrome) [ Time Frame: Week 16 ]
Mean change from baseline at each site visit for the following:
Change in markers of glucose control (C-peptide) results by central laboratory testing
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. Male and female participants from 18 to 75 years of age 2. Able and willing to provide informed consent and to comply with scheduled visits and study procedures 3. BMI ≥ 30 kg/m2 4. Presence of at least 3 of the 5 following criteria at screening: i. Increased waist circumference (males, ≥40 inches; females, ≥35 inches) ii. Fasting glucose ≥ 100 mg/dL in the last 3 months or an HgbA1C > 5.7% iii. Triglycerides ≥ 150 mg/dL or 1.69 mmol/L iv. HDL < 40 mg/dL or 1.03 mmol/L for males or < 50 mg/dL or 1.29 mmol/L for females v. Hypertension (systolic >130 mmHg and/or diastolic > 85 mmHg) or treated for hypertension
Exclusion Criteria:
- Significant medical condition, that in the opinion of the investigator, will place the participant at risk during the study or that will confound the study endpoints
- Active substance abuse including inhaled, oral, or injection drugs in the past 12 months
- Use of cannabis or cannabinoid-containing compounds within 90 days prior to screening
- Pregnancy, planned pregnancy, potential for pregnancy, breast feeding, or unwillingness to use highly effective birth control during the study
- History of significant liver disease or evidence of moderate to severe hepatic impairment
- History of epilepsy or intracranial surgery
- Diabetes requiring medication for management (a diagnosis of diabetes that is well controlled with diet and exercise is not exclusionary)
- Bariatric surgery, use of a GLP-1 agonists or other weight-loss drug, or significant weight change (> 5 kg or 11 pounds) in the past 3 months
- Participants taking any drug that may be used for weight loss (eg, liraglutide, semaglutide, tirzepatide, orlistat sibutramine phenylpropanolamine , mazindol , phentermine alone or in combination with topiramate, lorcaserin , naltrexone in combination with bupropion)
- Use of systemic corticosteroids (topical and inhaled corticosteroids are not excluded)
-
Participants with an active diagnosis or history of a significant psychiatric disorder, including but not limited to the following:
Major depression within the last 2 years
- Any history of a suicide attempt or suicidal ideation
- A history of other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
- Taking any of the following medications: antidepressants, atypical antipsychotics and mood stabilizers such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, lithium
- Score on the 9-question Patient Health Questionnaire (PHQ-9) of
- Current or active malignancy within the past 5 years, except for cancer in situ, or nonmelanoma skin cancer, such as basal cell or squamous cell carcinoma that has been completely resected
- A history thyroid disease; the only exception would be a participant who has undergone a complete thyroid ablation/resection
- QTc > 500 ms at baseline
- Any chronic medications with effects on blood pressure, lipids, or blood glucose started or changed within the past 3 months or at risk of requiring a change during the study
- Participants taking a strong inducer or inhibitor of cytochrome P450 3A4, 2D6, or 2C19 by screening; these medications are prohibited during the entire duration of the study
- Having taken any investigational compound within 30 days, or 5 half-lives of the drug, whichever is longer, before the screening visit
- Previous use of INV-202
- Participants that, in the opinion of the investigator, are unsuitable for the study or unlikely to comply with all study procedures and treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05891834
Show 24 study locations
| Responsible Party: | Inversago Pharma Inc. |
| ClinicalTrials.gov Identifier: | NCT05891834 |
| Other Study ID Numbers: |
INV-CL-107 |
| First Posted: | June 7, 2023 Key Record Dates |
| Last Update Posted: | May 9, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Obesity Metabolic Syndrome Syndrome Disease Pathologic Processes Overweight Overnutrition |
Nutrition Disorders Body Weight Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |